Genentech cancer biomarker leader named Foundation Med’s next CSO

boardroom
Hegde has previously worked on several Genentech-Foundation collaborations, including research into tumor mutational burden. (Pixabay)

Foundation Medicine brought on Genentech’s Priti Hegde, Ph.D., to be its new chief scientific officer and oversee its work in clinical product development and cancer genomics.

Hegde made the jump between the two Roche-owned siblings after 12 years at Genentech, where she most recently was senior director and principal scientist for oncology biomarker development.

There, she helped lead the group responsible for setting translational science strategies in cancer immunotherapy, across at least 18 therapeutic programs and more than 100 clinical trials. That includes the development and approvals of Tecentriq in the U.S. and Europe, as well as related diagnostic filings.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

She has also worked on several Genentech-Foundation collaborations, including research into tumor mutational burden. At Foundation, Hegde will also help oversee early-stage research, regulatory affairs and quality assurance.

RELATED: Roche inks $2.4B deal to buy out Foundation Medicine

“Dr. Hegde’s expertise, particularly in immunotherapy, will allow expansion of our research capabilities and further evolution in our approach to impacting patient care,” Foundation CEO Cindy Perettie said in a statement.

Perettie previously served as Roche’s senior VP of global oncology product strategy, helping to lead several oncology product launches for both Roche and Genentech before being named as Foundation’s chief this past January.

Hegde takes over for Michael Doherty, who will retire from Foundation Medicine in September, according to the company. Prior to joining Genentech, Hegde was the manager of disease and biomarker transcriptomics at GlaxoSmithKline.

RELATED: Bayer taps Roche's Foundation Medicine for Vitrakvi diagnostic development

Foundation was recently tapped by Bayer to develop genomic diagnostic tests for several cancer therapies—including its tissue-agnostic Vitrakvi in solid tumors with TRK fusion mutations, which it picked up from Loxo Oncology.

Suggested Articles

The FDA has cleared Drawbridge Health’s blood collection device designed to help monitor long-term blood sugar levels in people with diabetes.

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

FierceMedTech Fierce 15 winner 10x Genomics announced its plans for a $100 million IPO, on the Nasdaq using the symbol TXG.